Teva has obtained the long-awaited FDA approval for Ajobi auto-injected migraine treatment

Positive development in Teva: The pharmaceutical company has obtained the long-awaited FDA approval for Ajobi for auto-injected migraine treatment.
Teva will start marketing the syringe version towards the end of the current quarter (end of March) or early next quarter. The price of the syringe has not yet been determined and therefore the company does not yet provide estimates of the expected impact on revenue.
 Ajobi is a relatively new source drug of nature that entered the market about a year ago and is said to be one of the growth and profitability engines that will replace Copaxone. However, until now the new drug has not met expectations mainly in the face of fierce competition from drug giants Amjan and Eli Lilly who have developed a similar drug given in the syringe.
Giving FDA approval to the Ajobi syringe is expected to significantly improve Teva's state of the migraine prevention market, where it has been at a disadvantage to date because its drug was not available in the form of such a syringe.